Stan Bukofzer
Overview
Explore the profile of Stan Bukofzer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bukofzer S, Harris G, Cable E
Curr Res Pharmacol Drug Discov
. 2023 Aug;
5:100163.
PMID: 37608843
Institutional Protocol Number: Procedures were approved by the Ferring Research Institute (FRI) Institutional Animal Care and Use Committee (IACUC) on November 27, 2006 under protocol FRI 06-011, and by the...
2.
Bagger Y, Ravis W, Harris G, Bukofzer S
Clin Drug Investig
. 2023 Aug;
43(9):709-717.
PMID: 37606870
Background: OCE-205, a novel, selective vasopressin V1a receptor mixed agonist/antagonist with no V2 receptor activity, may treat the portal hypertension-related complications of end-stage liver disease with an improved therapeutic profile...
3.
Bukofzer S, Harris G, Song S, Cable E
J Exp Pharmacol
. 2023 Jul;
15:279-290.
PMID: 37469992
Purpose: Management of decompensated cirrhosis may include the use of vasoconstrictors that can lead to serious adverse events. OCE-205 was designed as a highly selective V1a receptor partial agonist, intended...
4.
Fernandez-Varo G, Jimenez W, Cable E, Gines P, Harris G, Bukofzer S
Biomed Pharmacother
. 2023 Jul;
165:115116.
PMID: 37418980
The vasopressin system has emerged as a therapeutic focus for lowering portal hypertension and reducing splanchnic vasodilation in patients with refractory ascites. Clinically available vasopressin agonists are limited by preferential...
5.
Safadi R, Rahimi R, Thabut D, Bajaj J, Bhamidimarri K, Pyrsopoulos N, et al.
Clin Transl Sci
. 2022 Mar;
15(6):1449-1459.
PMID: 35238476
Hepatic encephalopathy (HE) is a serious neurocognitive complication of liver dysfunction, often associated with elevated plasma ammonia. Ornithine phenylacetate (OP), a potent ammonia scavenger, is being evaluated for the treatment...
6.
Rahimi R, Safadi R, Thabut D, Bhamidimarri K, Pyrsopoulos N, Potthoff A, et al.
Clin Gastroenterol Hepatol
. 2020 Oct;
19(12):2626-2635.e7.
PMID: 33069881
Background & Aims: Hepatic encephalopathy (HE) is associated with increased morbidity, mortality, and health care resource use. In this phase 2b study, we evaluated the efficacy and safety of ornithine...
7.
Stravitz R, Gottfried M, Durkalski V, Fontana R, Hanje A, Koch D, et al.
Hepatology
. 2017 Oct;
67(3):1003-1013.
PMID: 29080224
Conclusion: OPA was well-tolerated in patients with ALI/ALF, and no safety signals were identified. Target [PA] was achieved at infusion rates of 20 g every 24 hours, leading to ammonia...
8.
Bukofzer S, Ayres J, Chavez A, Devera M, Miller J, Ross D, et al.
PDA J Pharm Sci Technol
. 2015 Feb;
69(1):123-39.
PMID: 25691720
No abstract available.
9.
Tejani F, Thompson R, Kristy R, Bukofzer S
Int J Cardiovasc Imaging
. 2014 Apr;
30(5):979-89.
PMID: 24737255
A multicenter, double-blind, randomized study was conducted to assess the effect of caffeine on regadenoson stress myocardial perfusion imaging (MPI). Subjects with a high likelihood of coronary artery disease underwent...
10.
Zinner N, Ammann L, Haas G, Janning S, He W, Bukofzer S
Neurourol Urodyn
. 2012 Sep;
32(4):308-13.
PMID: 23001509
Aims: To identify combinations of variables among overactive bladder (OAB) clinical trial subjects that allow prediction of those who are more--or less--likely to respond strongly to placebo, or to medication....